Compare Global E Online Ltd (GLBE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global E Online Ltd vs ResMed Inc. — how do they compare? Global E Online Ltd trades at $38.53 (market cap $6.55B), while ResMed Inc. trades at $200.93 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 4.4× Global E Online Ltd's market cap, and ResMed Inc. pays a 1.21% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.
| GLBE | RMD | |
|---|---|---|
Market Cap | $6.55B | $28.80B |
Sector | Technology | Health |
52-Week High | $41.59 | $293.73 |
52-Week Low | $27.54 | $182.82 |
Enterprise Value | $6.02B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLBE trades at $38.70, down 0.13% on the day, with a strong bullish technical signal from moving averages. The company reported Q1 2026 revenue growth of 33% year-over-year and raised full-year 2026 guidance, while maintaining a high P/E ratio of 58.18. Recent acquisition of Passport aims to enhance logistics capabilities, supporting future growth in cross-border e-commerce.
Outlook remains positive with 100% analyst buy ratings and a consensus price target of $38.00, though high valuation and recent insider sales present risks. Earnings momentum and strategic expansions provide upside potential, but investors should monitor competitive pressures and execution of growth initiatives.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
